Cannabidiol/tetrahydrocannabinol - Axim Biotech

Drug Profile

Cannabidiol/tetrahydrocannabinol - Axim Biotech

Alternative Names: CBD/THC gum; MedChew 1401; MedChew 1502; MedChew 1503; MedChew 1504; MedChew RX™; Tetrahydrocannabinol/cannabidiol - Axim Biotech

Latest Information Update: 23 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Axim Biotech
  • Class Analgesics; Antiemetics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dementia; Pain; Parkinson's disease; Restless legs syndrome
  • Preclinical Postherpetic neuralgia

Most Recent Events

  • 23 Mar 2017 Preclinical trials in Postherpetic neuralgia in USA (Buccal) (Axim Biotech pipeline, March 2017)
  • 16 Nov 2016 Axim Biotech receives patent allowance for cannabinoid-containing controlled-release chewing gum products in USA
  • 09 Nov 2016 Axim Biotech announces intention to submit NDA for Parkinson's disease, Dementia, Restless leg syndrome in 2021, 2022, 2020 (Axim Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top